Sean Hennessy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sean Hennessy has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Warren B. Bilker
4 shared publicationsBrian L. Strom
Center for Clinical Epidemiology & Biostatistics, Department of Biostatistics & Epidemiology, and Center for Education & Research in Therapeutics, University of Pennsylvania School of Medicine
3 shared publications- Brian L. Strom
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
3 shared publications Stephen E. Kimmel
Departments of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
3 shared publicationsBrian L Strom
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA, bPfizer, New York, NY 10017, USA, cDepartment of Psychiatry, University of Pennsylvania School of Medicine
2 shared publicationsCharles E. Leonard
2 shared publications
Latest Publications
- 1 December 2007
- Published by Wolters Kluwer Health in Medical Care
- Vol. 45 (12) , 1216-1220
Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS)
The Centers for Medicare and Medicaid Services (CMS) now make data from the Medicaid and Medicare programs available for research. Prior research has identified important issues in Medicaid data obtained from a commercial vendor. To perform exploratory analyses of Medicaid and Medicare data obtained through CMS. We obtained data from 1999 to 2000 for 5 large Medicaid programs (California, Florida, New York, Ohio, and Pennsylvania), together with the corresponding Medicare data for dual eligibles. We first plotted the number of prescription claims per month. We next plotted the frequency of hospitalization by age group, first using Medicaid data alone, then supplemented with Medicare data. We next plotted the frequency of claims with a diagnosis of complications of pregnancy and childbirth, and of prostate cancers, stratified by sex. The number of prescription claims per month was very stable. Because of cocoverage by Medicare, Medicaid data seemed to miss a substantial number of hospitalizations in those age 45 years and older. Diagnoses of complications of pregnancy and childbirth were uncommon in men and in women older than 60 years, and prostate cancer diagnoses were uncommon in women. In contrast to Medicaid data previously obtained from a commercial vendor, we found no evidence that prescription Medicaid data from CMS were incomplete. We were also reassured by the infrequency of gross diagnostic miscoding. Researchers using Medicaid data to study hospital outcomes should obtain supplemental Medicare data on dual eligibles for studies of persons aged 45 years and older.
- 1 December 2007
- Published by Wolters Kluwer Health in Medical Care
- Vol. 45 (12) , 1216-1220
Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS)
The Centers for Medicare and Medicaid Services (CMS) now make data from the Medicaid and Medicare programs available for research. Prior research has identified important issues in Medicaid data obtained from a commercial vendor. To perform exploratory analyses of Medicaid and Medicare data obtained through CMS. We obtained data from 1999 to 2000 for 5 large Medicaid programs (California, Florida, New York, Ohio, and Pennsylvania), together with the corresponding Medicare data for dual eligibles. We first plotted the number of prescription claims per month. We next plotted the frequency of hospitalization by age group, first using Medicaid data alone, then supplemented with Medicare data. We next plotted the frequency of claims with a diagnosis of complications of pregnancy and childbirth, and of prostate cancers, stratified by sex. The number of prescription claims per month was very stable. Because of cocoverage by Medicare, Medicaid data seemed to miss a substantial number of hospitalizations in those age 45 years and older. Diagnoses of complications of pregnancy and childbirth were uncommon in men and in women older than 60 years, and prostate cancer diagnoses were uncommon in women. In contrast to Medicaid data previously obtained from a commercial vendor, we found no evidence that prescription Medicaid data from CMS were incomplete. We were also reassured by the infrequency of gross diagnostic miscoding. Researchers using Medicaid data to study hospital outcomes should obtain supplemental Medicare data on dual eligibles for studies of persons aged 45 years and older.
- Open Access
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 166 (3) , 332-339
On the Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies
The use of propensity scores to adjust for measured confounding factors has become increasingly popular in cohort studies. However, their use in case-control and case-cohort studies has received little attention. The authors present some theory on the estimation and use of propensity scores in case-control and case-cohort studies and present the results of simulation studies that examine whether large-sample expectations are realized in studies of typical size. The application of propensity scores is less straightforward in case-control and case-cohort studies than in cohort studies. The authors' simulations revealed two potentially important issues. First, when using several potential approaches, there is artifactual effect modification of the odds ratio by level of propensity score. The magnitude of this phenomenon decreases as the sample size increases. Second, several potential approaches produce estimated propensity scores that do not converge to the true value as sample size increases and, thus, can fail to adjust fully for measured confounding factors. However, the magnitude of residual confounding appeared modest in our simulations. Researchers considering using propensity scores in case-control or case-cohort studies should consider the potential for artifactual effect modification and their reduced ability to control for potential confounding factors.
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 166 (3) , 332-339
Open AccessOn the Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies
The use of propensity scores to adjust for measured confounding factors has become increasingly popular in cohort studies. However, their use in case-control and case-cohort studies has received little attention. The authors present some theory on the estimation and use of propensity scores in case-control and case-cohort studies and present the results of simulation studies that examine whether large-sample expectations are realized in studies of typical size. The application of propensity scores is less straightforward in case-control and case-cohort studies than in cohort studies. The authors' simulations revealed two potentially important issues. First, when using several potential approaches, there is artifactual effect modification of the odds ratio by level of propensity score. The magnitude of this phenomenon decreases as the sample size increases. Second, several potential approaches produce estimated propensity scores that do not converge to the true value as sample size increases and, thus, can fail to adjust fully for measured confounding factors. However, the magnitude of residual confounding appeared modest in our simulations. Researchers considering using propensity scores in case-control or case-cohort studies should consider the potential for artifactual effect modification and their reduced ability to control for potential confounding factors.
- 1 September 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (9) , 1342-1347
Effectiveness of a Two‐Part Educational Intervention to Improve Hypertension Control: A Cluster‐Randomized Trial
Study Objective. To measure the effectiveness of a multifaceted educational intervention to improve ambulatory hypertension control.Design. Cluster‐randomized trial.Setting. Academic health system using an ambulatory electronic medical record.Subjects. A total of 10,696 patients with a diagnosis of hypertension cared for by 93 primary care providers.Intervention. Academic detailing, provision of provider‐specific data about hypertension control, provision of educational materials to the provider, and provision of educational and motivational materials to patients.Measurements and Main Results. The primary outcome was blood pressure control, defined as a blood pressure measurement below 140/90 mm Hg, and was ascertained from electronic medical records over 6 months of follow‐up. We determined the adjusted odds ratio for the association between the intervention and the achievement of controlled blood pressure. When we accounted for clustering by provider, this adjusted odds ratio was 1.13 (95% confidence interval 0.87–1.47). Adjusted odds ratios were 1.03 (95% confidence interval 0.78–1.36) in patients whose blood pressure was controlled at baseline and 1.25 (95% confidence interval 0.94–1.65) in those whose blood pressure was not. These odds ratios were not significantly different (p=0.11).Conclusions. These results were consistent with no effect or, at best, a relatively modest effect of the intervention among patients with hypertension. Had we not included a concurrent control group, the data would have provided an unduly optimistic view of the effectiveness of the program. The effectiveness of future interventions may be improved by focusing on patients whose blood pressure is uncontrolled at baseline.
- 1 September 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (9) , 1342-1347
Effectiveness of a Two‐Part Educational Intervention to Improve Hypertension Control: A Cluster‐Randomized Trial
Study Objective. To measure the effectiveness of a multifaceted educational intervention to improve ambulatory hypertension control.Design. Cluster‐randomized trial.Setting. Academic health system using an ambulatory electronic medical record.Subjects. A total of 10,696 patients with a diagnosis of hypertension cared for by 93 primary care providers.Intervention. Academic detailing, provision of provider‐specific data about hypertension control, provision of educational materials to the provider, and provision of educational and motivational materials to patients.Measurements and Main Results. The primary outcome was blood pressure control, defined as a blood pressure measurement below 140/90 mm Hg, and was ascertained from electronic medical records over 6 months of follow‐up. We determined the adjusted odds ratio for the association between the intervention and the achievement of controlled blood pressure. When we accounted for clustering by provider, this adjusted odds ratio was 1.13 (95% confidence interval 0.87–1.47). Adjusted odds ratios were 1.03 (95% confidence interval 0.78–1.36) in patients whose blood pressure was controlled at baseline and 1.25 (95% confidence interval 0.94–1.65) in those whose blood pressure was not. These odds ratios were not significantly different (p=0.11).Conclusions. These results were consistent with no effect or, at best, a relatively modest effect of the intervention among patients with hypertension. Had we not included a concurrent control group, the data would have provided an unduly optimistic view of the effectiveness of the program. The effectiveness of future interventions may be improved by focusing on patients whose blood pressure is uncontrolled at baseline.
- 16 March 2006
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 98 (3) , 311-313
Use of Health Care Databases in Pharmacoepidemiology
Pharmacoepidemiology is the study of the use and effects of medications in populations. Large health care databases are often used to address research questions within pharmacoepidemiology. This paper briefly describes the kinds of research questions that can be addressed using pharmacoepidemiology databases, provides an overview of pharmacoepidemiologic databases, describes some differences between medical records and administrative databases, discusses factors that should be considered when choosing a database for a particular study, and considers what the future holds.
- 16 March 2006
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 98 (3) , 311-313
Use of Health Care Databases in Pharmacoepidemiology
Pharmacoepidemiology is the study of the use and effects of medications in populations. Large health care databases are often used to address research questions within pharmacoepidemiology. This paper briefly describes the kinds of research questions that can be addressed using pharmacoepidemiology databases, provides an overview of pharmacoepidemiologic databases, describes some differences between medical records and administrative databases, discusses factors that should be considered when choosing a database for a particular study, and considers what the future holds.
- 7 March 2006
- Published by Wiley
- p. 831-839
The Future of Pharmacoepidemiology
- 7 March 2006
- Published by Wiley
- p. 37-57
Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies
- 7 March 2006
- Published by Wiley
- p. 37-57
Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies
- 11 August 2004
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 13 (8) , 503-504
Disproportionality analyses of spontaneous reports
- 11 August 2004
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 13 (8) , 503-504
Disproportionality analyses of spontaneous reports
- 20 July 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (2) , 157-158
Is Improved Survival a Class Effect of Angiotensin-Converting Enzyme Inhibitors?
- 20 July 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (2) , 157-158
Is Improved Survival a Class Effect of Angiotensin-Converting Enzyme Inhibitors?